Number of pages: 100 | Report Format: PDF | Published date: October 04, 2022
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
Report Attribute |
Details |
Market size value in 2021 |
US$ 990 million |
Revenue forecast in 2030 |
US$ 1510 million |
Growth Rate |
CAGR of 4.8% from 2022 to 2030 |
Base year for estimation |
2021 |
Forecast period |
2022-2030 |
Segments covered |
Treatment Type, Influenza Type, Distribution Channel, and Region. |
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global influenza medication market was valued at US$ 990 million in 2021 and is expected to register a revenue CAGR of 4.8% to reach US$ 1510 million by 2030.
Market Fundamentals
Influenza is a common contagious viral infection affecting the respiratory system. The symptoms of influenza include high fever, chills, cold, cough, headache, and body pain. Influenza medications may either target the influenza virus inside an infected body or can provide relief from the disease symptoms. Children and adults aged 65 or above are most prone to this disease. According to the estimate from a real-time pharmacy surveillance program by the Japanese Medical Association and the National Institute of Infectious Diseases, the infection rate in people aged 65 or above is increasing significantly from 28.4% in 2019 to 35.3% in 2040. Flu or influenza is a communicable disease caused by airborne respiratory droplets, contact with a contaminated surface or an infected person, weather changes, etc. Generally, people recover from the disease, but if it lasts for a long time, it may have some serious effects like pneumonia.
[6348543]
Market Dynamics
A significant increase in the number of influenza patients and increased research and development activities for drug discovery are likely to boost the revenue growth of the global influenza medication market. Increased technological advancements in novel medications are expected to present a revenue growth opportunity during the forecast period. However, the high adoption of influenza vaccines is expected to hamper the market revenue growth to some extent.
Market Ecosystem
The global influenza medication market is analyzed from four perspectives: treatment type, Influenza type, distribution channel, and region.
Global Influenza Medication Market by Treatment Type
[43343232]
Based on treatment type, the global influenza medication market is segmented into oseltamivir phosphate, baloxavir, marboxil, and others (including zanamivir).
The oseltamivir phosphate segment dominates the market in terms of revenue share. The high revenue share of this segment can be attributed to the fact that this drug is widely prescribed and has high efficacy in the treatment of influenza. The drug is also effective in blocking the action of both the influenza type i.e., type A and type B, reducing its symptoms.
Other segments of the treatment are also expected to register high revenue growth during the forecast period because of the rising global prevalence rate of influenza.
Global Influenza Medication Market by Influenza Type
Based on the influenza type, the global medication market is segmented into influenza A and influenza B.
Influenza type A dominates the global influenza medication market in terms of revenue share. This revenue growth of this segment is attributed to an increased number of patients suffering from influenza A with the seasonal epidemic. It accounts for approximately 75% of the total influenza infection. Influenza type A has two sub-segmentations namely, hemagglutinin and neuraminidase. Further, hemagglutinin has 18 subtypes, and the neuraminidase type has 11 subtypes. These variations make it more infectious.
Global Influenza Medication Market by Distribution Channel
Based on distribution channels, the global influenza medication market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies.
The retail pharmacy segment accounts for the largest revenue share owing to an increased number of retail pharmacies business around the world, improving the availability of influenza drugs. It also reduces the time required for delivery, as seen in online pharmacies.
The revenue growth of other segments like online pharmacies is also increasing due to the increasing popularity of e-commerce.
Global Influenza Medication Market by Region
Based on region, the global influenza medication market is segmented into North America, Europe, Asia Pacific, and the Rest of the world.
North America dominates the global influenza medication market in terms of revenue share. The high prevalence of influenza, increasing research and development activities, and the presence of a large geriatric population, are the major factors responsible for the market revenue growth in this region.
The Asia Pacific accounts for the second-largest revenue share in the global influenza medication market. The major factors driving the high revenue growth in this region include the high prevalence of influenza and government initiatives for controlling disease.
Europe is also expected to register significant revenue growth during the forecast period due to an increased rate of the disease as well as an increasing immunocompromised geriatric population.
Competitive Landscape
The prominent market players operating in the global influenza medication market are:
Strategic Developments
North America dominates the global influenza medication market in terms of revenue.
Sanofi S.A, Lupin Limited, Teva Pharmaceutical Industries Ltd., Shionogi & Co. Ltd, and Macleods Pharmaceutical Ltd. are the top five players in the global influenza medication market.
The global influenza medication market was valued at US$ 990 million and is expected to reach US$ 1510 million by 2030.
*Insights on financial performance is subject to availability of information in public domain